A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals. / Ohrstrom, Caroline C.; Hansen, Dorte L.; Kielgast, Urd Lynge; Hartmann, Bolette; Holst, Jens Juul; Worm, Dorte.
In: Obesity Surgery, Vol. 30, 2020, p. 1605-1610.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals
AU - Ohrstrom, Caroline C.
AU - Hansen, Dorte L.
AU - Kielgast, Urd Lynge
AU - Hartmann, Bolette
AU - Holst, Jens Juul
AU - Worm, Dorte
PY - 2020
Y1 - 2020
N2 - Post-bariatric hypoglycemia (PBH) can be a serious complication after Roux-en-Y gastric bypass (RYGB), and treatment with somatostatin analogs has been suggested. We investigated the acute effects of three different doses of pasireotide (75 mu g, 150 mu g, and 300 mu g) on the postprandial glucose metabolism in five RYGB-operated individuals with PBH using a mixed meal test. All three doses prevented hypoglycemia but were associated with a notable increase in postprandial hyperglycemia. Moreover, all doses greatly diminished insulin, C-peptide, and glucagon-like peptide-1 responses. Considering its strong hyperglycemic potential, we suggest that pasireotide should be administered carefully in RYGB-operated individuals with PBH, and if necessary, a 75 mu g dose seems sufficient to prevent hypoglycemia.
AB - Post-bariatric hypoglycemia (PBH) can be a serious complication after Roux-en-Y gastric bypass (RYGB), and treatment with somatostatin analogs has been suggested. We investigated the acute effects of three different doses of pasireotide (75 mu g, 150 mu g, and 300 mu g) on the postprandial glucose metabolism in five RYGB-operated individuals with PBH using a mixed meal test. All three doses prevented hypoglycemia but were associated with a notable increase in postprandial hyperglycemia. Moreover, all doses greatly diminished insulin, C-peptide, and glucagon-like peptide-1 responses. Considering its strong hyperglycemic potential, we suggest that pasireotide should be administered carefully in RYGB-operated individuals with PBH, and if necessary, a 75 mu g dose seems sufficient to prevent hypoglycemia.
KW - Gastric bypass
KW - Hypoglycemia
KW - Hyperglycemia
KW - Pasireotide
KW - Somatostatin analogs
U2 - 10.1007/s11695-019-04248-x
DO - 10.1007/s11695-019-04248-x
M3 - Journal article
C2 - 31709494
VL - 30
SP - 1605
EP - 1610
JO - Obesity Surgery
JF - Obesity Surgery
SN - 0960-8923
ER -
ID: 230692191